Medicines | European Medicines Agency

Medicines

For help on how to get the results you want, see our search tips.

Search results

Categories

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

Product number

Authorisation status

ATC code

Marketing authorisation date

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

Medicine type

Therapeutic area

Last updated

First published

8 results

Sort by

List item

Human medicine European public assessment report (EPAR): Breyanzi (updated)

CD19-directed genetically modified autologous cell-based product consisting of purified CD8+ T-cells (CD8+ cells), CD19-directed genetically modified autologous cell-based product consisting of purified CD4+ T cells (CD4+ cells), Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Mediastinal Neoplasms
Date of authorisation: 04/04/2022, , Revision: 1, Authorised, Last updated: 25/05/2023
List item

Human medicine European public assessment report (EPAR): Lunsumio

mosunetuzumab, Lymphoma, Follicular
Date of authorisation: 03/06/2022, , , , Revision: 1, Authorised, Last updated: 20/04/2023
List item

Human medicine European public assessment report (EPAR): Yescarta

Axicabtagene ciloleucel, Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 23/08/2018, , , Revision: 11, Authorised, Last updated: 30/01/2023
List item

Human medicine European public assessment report (EPAR): Copiktra

duvelisib, Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular
Date of authorisation: 19/05/2021, , Revision: 2, Authorised, Last updated: 13/07/2022
List item

Human medicine European public assessment report (EPAR): Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto)

lenalidomide hydrochloride monohydrate, Multiple Myeloma; Myelodysplastic Syndromes; Lymphoma, Follicular; Lymphoma, Mantle-Cell
Date of authorisation: 11/02/2021, , Revision: 3, Authorised, Last updated: 22/12/2021
List item

Human medicine European public assessment report (EPAR): Lenalidomide Krka d.d.

lenalidomide hydrochloride hydrate, Multiple Myeloma; Lymphoma, Follicular; Myelodysplastic Syndromes
Date of authorisation: 11/02/2021, , Revision: 2, Authorised, Last updated: 17/12/2021
List item

Human medicine European public assessment report (EPAR): Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka)

lenalidomide hydrochloride monohydrate, Multiple Myeloma; Lymphoma, Follicular
Date of authorisation: 11/02/2021, , Revision: 3, Authorised, Last updated: 17/12/2021
List item

Human medicine European public assessment report (EPAR): Zevalin

ibritumomab tiuxetan, Lymphoma, Follicular
Date of authorisation: 16/01/2004, Revision: 23, Authorised, Last updated: 29/06/2021